Medtronic And Titan Medical Sign Licensing, Development Agreements For Robotic Surgeries
Medtronic has agreed to licensing and development agreements with cash-strapped surgical robotics company Titan receiving payments up to $31m pending certain milestones.
You may also be interested in...
Medtronic's revenue for the fourth quarter of fiscal 2020 was down 25% year-year-over due to the COVID-19 pandemic. The hardest-hit segment was restorative therapies, which reported a 33% year-over-year decline in the quarter due to the drop off in deferrable procedures and capital purchases. For the full fiscal year, Medtronic's revenue was down 4.2% to $28.9bn.
Women’s health startups focusing on areas of high unmet need such as menopause, infertility, preventive care and post-partum care will continue to attract investors in 2024. Meanwhile, machine learning and AI, as well as next-generation treatments such as psychedelic therapy, stand to drive advancements in the space.
Medtech Insight's News We're Watching highlights medtech industry news developments you may have missed over the last few weeks.